

Supplementary Table. Review of reported cases of CAA-RI by comparing the results of CSF markers, ApoE genotypes, FDG-PET and amyloid PET studies

Study	Patients (N)	CSF markers					ApoE genotype (N)	FDG-PET (N)	Amyloid PET (N)
		Anti-A β antibody (ng/mL)	A β_{40} (pg/mL)	A β_{42} (pg/mL)	Total Tau (pg/mL)	Phosphorylated Tau (pg/mL)			
Piazza et al. ¹ (2013)	Total: 10 ApoE: 9	52 $\pm$ 21.9 ▲	2,107 $\pm$ 446.4 ▼	640 $\pm$ 338.3	335.9 $\pm$ 312.7	47.0 $\pm$ 30.5	E3/E3: 4 E3/E4: 1 E4/E4: 4	-	-
Sengoku et al. ² (2014)	2	-	-	-	-	-	-	Decreased uptake in the lesion: 2	AD-like pattern: 1 Increased uptake in the lesion: 1
DiFrancesco et al. ³ (2015)	Total: 2 PET: 1	-	-	-	-	-	E3/E3: 1 E4/E4: 1	-	Decreased uptake in the lesion: 1
Crosta et al. ⁴ (2015)	1	55.9 ▲	-	-	-	-	E4/E4: 1	-	-
Boncoraglio et al. ⁵ (2015)	1	55.9 ▲	-	72 ▼	698 ▲	105 ▲	E4/E4: 1	-	-
Carmona-Iragui et al. ⁶ (2016)	4	51.9 $\pm$ 11.8 ▲	5,115 $\pm$ 1,560.1 ▼	274 $\pm$ 72.7 ▼	445.8 $\pm$ 268.4 ▲	60 $\pm$ 27.8 ▲	E3/E3: 1 E3/E4: 1 E4/E4: 2	-	Decreased uptake in the lesion: 2
Renard et al. ⁷ (2018)	Total: 25 CSF: 20 PET: 11 ApoE: 22	-	4,946 ▼ (1,660-9,867)	312 ▼ (66-476)	474 ▲ (91-1,200)	49 (15-71)	Non-E4 alleles: 10 E4 heterozygote: 4 E4 homozygote: 8	-	SUVR _{pons} values were higher in CAA-RI group than CAA group, whereas SUVR _{cerebellum} showed no difference ($p=0.037$)
Renard et al. ⁸ (2018)	9	-	11,187 (7,701-21,205)	448 ▼ (191-564)	352 ▲ (91-1,200)	55 (15-71)	E3/E3: 2 E3/E4: 2 E4/E4: 5	-	SUVR _{pons} values showed negative correlation to CSF A β_{40} level ($p=0.008$)
Coulette et al. ⁹ (2019)	28	-	4,353 $\pm$ 2,495 ▼	312 $\pm$ 133 ▼	439 $\pm$ 392 ▲	44 $\pm$ 14	-	-	-

Cutoff values used in this study were A β_{42} , <485 pg/mL; total Tau, >326 pg/mL; and phosphorylated Tau, >57 pg/mL.¹⁰ CAA-RI; cerebral amyloid angiopathy-related inflammation, CSF; cerebrospinal fluid, ApoE; apolipoprotein E, FDG; fluorodeoxyglucose, PET; positron emission tomography, AD; Alzheimer's disease, SUVR; standardized uptake value ratio.

SUPPLEMENTARY REFERENCES

- Piazza F, Greenberg SM, Savoiardo M, Gardinetti M, Chiapparini L, Raicher I, et al. Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies. *Ann Neurol* 2013;73:449-458.
- Sengoku R, Matsushima S, Murakami Y, Fukuda T, Tokumaru AM, Hashimoto M, et al. ¹¹C-PiB PET imaging of encephalopathy associated with cerebral amyloid angiopathy. *Intern Med* 2014;53:1997-2000.
- DiFrancesco JC, Touat M, Caulo M, Gallucci M, Garcin B, Levy R, et al. Recurrence of cerebral amyloid angiopathy-related inflammation: a report of two cases from the iCA β International Network. *J Alzheimers Dis* 2015;46:1071-1077.
- Crosta F, Orlandi B, De Santis F, Passalacqua G, DiFrancesco JC, Piazza F, et al. Cerebral amyloid angiopathy-related inflammation: report of a case with very difficult therapeutic management. *Case Rep Neurol Med* 2015;2015:483020.
- Boncoraglio GB, Piazza F, Savoiardo M, Farina L, DiFrancesco JC, Prioni S, et al. Prodromal Alzheimer's disease presenting as cerebral amyloid angiopathy-related inflammation with spontaneous amyloid-related imaging abnormalities and high cerebrospinal fluid anti-A β autoantibodies. *J Alzheimers Dis* 2015;45:363-367.
- Carmona-Iragui M, Fernandez-Arcos A, Alcolea D, Piazza F, Morenas-Rodriguez E, Anton-Aguirre S, et al. Cerebrospinal fluid anti-amyloid-beta autoantibodies and amyloid PET in cerebral amyloid angiopathy-related inflammation. *J Alzheimers Dis* 2016;50:1-7.
- Renard D, Tatu L, Collombier L, Wacogne A, Aygnac X, Charif M, et al. Cerebral amyloid angiopathy and cerebral amyloid angiopathy-related inflammation: comparison of hemorrhagic and DWI MRI features. *J Alzheimers Dis* 2018;64:1113-1121.
- Renard D, Collombier L, Demattei C, Wacogne A, Charif M, Aygnac X, et al. Cerebrospinal fluid, MRI, and florbetaben-PET in

- cerebral amyloid angiopathy-related inflammation. *J Alzheimers Dis* 2018;61:1107-1117.
9. Coulette S, Renard D, Lehmann S, Raposo N, Arquizan C, Charif M, et al. A clinico-radiological study of cerebral amyloid angiopathy-related inflammation. *Cerebrovasc Dis* 2019;48:38-44.
10. Park SA, Chae WS, Kim HJ, Shin HS, Kim S, Im JY, et al. Cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease in South Korea. *Alzheimer Dis Assoc Disord* 2017;31:13-18.